Investigation of the variability of etoposide pharmacokinetics in children.
The interindividual variation of etoposide pharmacokinetics under different therapeutic schedules and the rationale of dose reduction in young children and newborns were investigated in the present study. We evaluated pharmacokinetic parameters during short-term infusion in 21 therapy cycles (18 children) on different therapeutic schedules (66-200 mg/m2). In 33 patients state levels (Css) during continuous infusion of 125 mg/m2/96 h were analyzed by an HPLC-method. During short-term infusion half-life (3.3 +/- 0.7 h) and total body clearance (26 +/- 6 ml/min/m2) showed a relatively narrow range. Calculation of the area under the curve was standardized to a dosage of 100 mg/m2 (AUC/[100 mg/m2]). The AUC then was 68 +/- 17 (micrograms.h/ml)/(100 mg/m2) with a coefficient of variation of 25%. In the subgroup of 10 patients who received 150 mg/m2 the AUC was 106 +/- 15 micrograms.h/ml with only 14% coefficient of variation. In children < 2 years, pharmacokinetic parameters were within the normal range. Calculation of the doses the short-term infusion per kg resulted in a dose reduction or 31% (mean, n = 5) and in 22% (mean) lower AUC's. With continuous infusion of 125 mg/m2 etoposide the interpatient variability was greater with a 33% coefficient of variation of the Css (4.4 +/- 1.4 micrograms/ml; n = 24). Calculation of the doses per kg (age < 1 year) or 2/3.kg resulted in reduced Css. Standardization of these levels showed Css (125 mg/m2) of 4.6 +/- 1.4 micrograms/ml and a coefficient of variation of 31%. Interpatient variability of etoposide pharmacokinetics at least during short-term infusion is limited. Dose reduction is not substantiated in children < 2 years by our pharmacokinetic data.